Roche and Catalent team up in $600m conjugation tech deal
Roche has collaborated with CDMO Catalent to access the SMARTag protein-modification and conjugation technology in a deal that could be worth up to $618m (€568m).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs